High-resolution Mass Spectrometry (HRMS) in Biologics Characterization

As biologic therapeutics become increasingly complex, analytical characterization requirements continue to evolve.

Modern biologics—including monoclonal antibodies (mAbs), bispecific antibodies, fusion proteins, antibody-drug conjugates (ADCs), and other complex modalities—contain intricate structural features that directly influence efficacy, safety, stability, and manufacturability.

Traditional analytical approaches remain essential, but they are often insufficient for comprehensive molecular-level characterization.

High-resolution mass spectrometry (HRMS) has therefore become one of the most powerful analytical technologies in biologics development.

By enabling precise molecular mass determination, structural characterization, impurity profiling, and post-translational modification (PTM) analysis, HRMS plays a critical role across:

• Discovery
• Developability assessment
• Process development
• CMC analytical support
• Comparability studies
• Regulatory submissions
  
  

In this article, we explore how HRMS supports biologics characterization, the major analytical applications of HRMS, and why integrated mass spectrometry strategies are becoming increasingly important for modern biologics development.

Why Biologics Characterization Is Increasingly Complex

Unlike small molecules, biologics are inherently heterogeneous. Even highly controlled manufacturing processes can generate variability in:

• Glycosylation
• Oxidation
• Deamidation
• Aggregation
• Fragmentation
• Charge variants
• Conjugation patterns
  
  

These structural attributes can significantly impact:

• Biological activity
• Pharmacokinetics
• Immunogenicity
• Stability
• Product quality

As biologic modalities continue to diversify, analytical strategies must provide increasingly detailed molecular insight. Regulatory agencies now expect extensive characterization of:

• Critical quality attributes (CQAs)
• Product heterogeneity
• Process-related impurities
• Structural integrity
• Comparability between batches

This has accelerated the adoption of HRMS as a core analytical technology in biologics development.

What Is High-Resolution Mass Spectrometry (HRMS)?

High-resolution mass spectrometry is an analytical technique capable of accurately measuring molecular masses with extremely high precision.

Compared with conventional mass spectrometry, HRMS provides:

• Higher mass accuracy
• Greater resolving power
• Enhanced sensitivity
• Improved structural characterization
• Better detection of low-abundance species

Common HRMS platforms used in biologics characterization include:

HRMS is frequently integrated with:

• Liquid chromatography (LC)
• Capillary electrophoresis (CE)
• Native MS workflows
• Multi-attribute methods (MAM)

Together, these technologies provide comprehensive structural characterization across multiple analytical levels.

Major Applications of HRMS in Biologics Characterization

1. Intact Mass Analysis

Intact mass analysis is one of the foundational applications of HRMS in biologics characterization.vThis approach measures the molecular mass of the entire protein without enzymatic digestion.

Intact mass analysis supports:

• Molecular identity confirmation
• Detection of truncations
• Identification of glycoform distributions
• Conjugation analysis
• Product heterogeneity assessment

For antibody-drug conjugates (ADCs), intact mass analysis can also support:

• Drug-antibody ratio (DAR) characterization
• Payload distribution analysis
• Linker stability assessment

Because intact biologics often generate highly complex spectra, high resolving power is essential.

HRMS enables accurate deconvolution and interpretation of heterogeneous molecular populations.

2. Peptide Mapping and PTM Analysis

Peptide mapping is one of the most widely used HRMS workflows in biologics development. In peptide mapping workflows:

• Proteins are enzymatically digested
• Peptides are separated by LC
• HRMS identifies peptide masses and sequences

This enables detailed characterization of:

• Amino acid sequence
• Post-translational modifications (PTMs)
• Oxidation sites
• Deamidation
• Glycosylation
• Disulfide bond integrity

PTM characterization is particularly important because even minor structural modifications may alter:

• Potency
• Stability
• Immunogenicity
• Pharmacokinetics

HRMS provides the sensitivity and resolution necessary to detect low-abundance modifications that may be missed by lower-resolution techniques.

3. Glycosylation Profiling

Glycosylation is one of the most critical quality attributes for many biologics. Differences in glycan structure can significantly affect:

• Effector function
• Serum half-life
• Stability
• Immunogenicity
• Clinical efficacy

HRMS enables detailed glycosylation analysis through:

• Released glycan analysis
• Glycopeptide profiling
• Intact glycoprotein characterization

These workflows help characterize:

• Glycan composition
• Glycosylation site occupancy
• Microheterogeneity
• Batch-to-batch consistency

As glycoengineering strategies become more sophisticated, HRMS-based glycan characterization is becoming increasingly important.

4. Multi-Attribute Method (MAM) Workflows

Multi-attribute methods (MAM) represent a rapidly growing application of HRMS in biologics analytics. MAM workflows use LC-HRMS to simultaneously monitor multiple product quality attributes within a single analytical method.

Attributes commonly monitored include:

• Oxidation
• Deamidation
• Glycosylation
• Fragmentation
• Sequence variants
• Product impurities

Compared with traditional testing strategies, MAM offers:

• Greater analytical efficiency
• Improved process understanding
• Reduced assay redundancy
• Enhanced product monitoring

MAM is increasingly being evaluated as a potential replacement for multiple conventional assays in quality control workflows.

5. Process Impurity Analysis

Biologics manufacturing processes can introduce a wide range of impurities. These may include:

• Host cell proteins (HCPs)
• Residual enzymes
• Media components
• Product fragments
• Aggregates
• Leachables and extractables

HRMS supports highly sensitive impurity profiling and identification. Because many impurities exist at trace levels, the sensitivity and selectivity of HRMS are especially valuable. Comprehensive impurity analysis supports:

• Product safety
• Regulatory compliance
• Process optimization
• Manufacturing consistency

6. Comparability Studies

Comparability assessment is a critical component of biologics development. Sponsors may need to demonstrate comparability after:

• Manufacturing process changes
• Scale-up
• Site transfers
• Formulation modifications

HRMS provides detailed molecular-level comparison between products and batches.

Analytical comparability studies may evaluate:

• PTM profiles
• Glycosylation patterns
• Charge variants
• Product heterogeneity
• Impurity distributions

Because HRMS provides highly sensitive structural data, it has become an increasingly important tool in comparability assessment strategies.

HRMS in ADC Characterization

Antibody-drug conjugates represent one of the most analytically challenging biologic modalities. Their complexity arises from:

• Heterogeneous payload distribution
• Linker instability
• DAR variability
• Multiple circulating species

HRMS supports ADC characterization through:

• Intact mass analysis
• DAR profiling
• Payload localization
• Stability assessment
• Catabolite analysis

Native HRMS workflows are increasingly used to evaluate ADC structural integrity under physiologically relevant conditions.

As ADC pipelines expand, HRMS is becoming central to advanced characterization workflows.

Regulatory Expectations for HRMS-Based Characterization

Regulatory agencies increasingly expect comprehensive structural characterization for biologics. HRMS-generated data often support:

• IND submissions
• BLA filings
• Comparability packages
• Process validation
• Product quality assessments

Agencies generally expect analytical methods to demonstrate:

• Sensitivity
• Specificity
• Accuracy
• Reproducibility
• Scientific justification

In addition, regulators increasingly recognize HRMS as a powerful platform for advanced product characterization and impurity assessment.

Challenges in HRMS Implementation

Despite its advantages, HRMS implementation can be complex. Common challenges include:

• Large data volume
• Complex spectral interpretation
• Method standardization
• Instrument sensitivity optimization
• Data processing workflows
• Bioinformatics integration

Biologics characterization also frequently requires:

• Orthogonal analytical techniques
• Cross-functional interpretation
• Highly specialized expertise

As a result, successful HRMS programs often depend on integrated analytical teams with expertise in:

• Mass spectrometry
• Protein chemistry
• Bioinformatics
• CMC analytics
• Regulatory science

Best Practices for HRMS in Biologics Development

1. Integrate HRMS Early in Development

Early characterization improves:

• Developability assessment
• Risk identification
• Process understanding
• Product quality strategy

2. Use Orthogonal Characterization Approaches

HRMS is most powerful when combined with complementary techniques such as:

• Chromatography
• Electrophoresis
• Functional bioassays
• Spectroscopic methods

3. Focus on Critical Quality Attributes (CQAs)

Analytical strategies should prioritize attributes most relevant to:

• Clinical performance
• Stability
• Immunogenicity
• Regulatory expectations

4. Build Scalable Data Analysis Workflows

As HRMS datasets become more complex, robust data processing and interpretation pipelines become increasingly important.

5. Align Characterization With Regulatory Strategy

Analytical characterization plans should support:

• Regulatory submissions
• Comparability assessments
• Lifecycle management
• Quality control strategy

The Future of HRMS in Biologics Characterization

HRMS technologies continue to evolve rapidly. Emerging trends include:

• Native MS workflows
• Top-down proteomics
• AI-assisted spectral interpretation
• Real-time process monitoring
• Automated MAM platforms
• Ultra-high-resolution structural analysis

Future biologics characterization strategies will increasingly rely on integrated HRMS ecosystems capable of supporting:

• Discovery
• Process development
• Clinical development
• Manufacturing
• Quality control

Organizations with strong HRMS capabilities will be better positioned to support next-generation biologics and increasingly complex therapeutic modalities.

Conclusion

High-resolution mass spectrometry has become one of the most important analytical technologies in modern biologics characterization.

Its ability to provide detailed structural, molecular, and impurity-related information makes HRMS essential across:

• Developability assessment
• Product characterization
• Comparability studies
• Process impurity analysis
• ADC analytics
• Regulatory support

As biologic therapeutics continue to evolve in complexity, integrated HRMS strategies will play an increasingly central role in ensuring product quality, regulatory confidence, and successful clinical development.

References

• Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianférani S. Characterization of therapeutic antibodies and related products. Analytical Chemistry. 2013;85(2):715–736.
• Rogers RS, Nightlinger NS, Livingston B, Campbell P, Bailey R, Balland A. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. mAbs. 2015;7(5):881–890.
• Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrometry Reviews. 2009;28(1):147–176.
• ICH Q6B. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. International Council for Harmonisation.
• FDA. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. U.S. Food and Drug Administration.
• Yang Y, Wang G, Song T, et al. Applications of mass spectrometry in biopharmaceutical analysis. Current Pharmaceutical Biotechnology. 2017;18(11):915–926.
• Dobson R, Fenn JB. Electrospray ionization-mass spectrometry of proteins and peptides. Proceedings of the National Academy of Sciences. 1989;86(24):9784–9788.
• Xu K, Liu L, Saad OM, et al. Characterization of intact antibody-drug conjugates by LC-MS. Journal of Chromatography B. 2011;879(13–14):983–990.
• Huang RY, Chen G. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry. Analytical and Bioanalytical Chemistry. 2014;406:6541–6558.
• Haberger M, Leiss M, Heidenreich AK, et al. Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry. mAbs. 2016;8(2):331–339.
• Gahoual R, Burr A, Busnel JM, Beck A, Franc V, Leize-Wagner E. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. mAbs. 2013;5(3):479–490.
• Doneanu CE, Anderson M, Williams BJ, et al. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive LC/MS approaches. MAbs. 2012;4(1):24–44.
• Ren D, Pipes GD, Liu D, et al. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Analytical Biochemistry. 2009;392(1):12–21.
• Schiel JE, Davis DL, Borisov OV. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization. American Chemical Society; 2015.
• Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews Drug Discovery. 2012;11(7):527–540.